Canada - English - Health Canada

sandoz canada incorporated - timolol (timolol maleate) - solution (extended release) - 0.25% - timolol (timolol maleate) 0.25% - beta-adrenergic agents

Canada - English - Health Canada

sandoz canada incorporated - timolol (timolol maleate) - solution (extended release) - 0.5% - timolol (timolol maleate) 0.5% - beta-adrenergic agents

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution usp is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see warnings ); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see warnings ); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product. the drop-tainer® bottle is designed to assure the delivery of a precise dose of medication. before using your drop-tainer bottle, read the complete instructions carefully. 1. if you use other topically applied ophthalmic medications, they should be administered at least 10 minutes before or after timolol maleate ophthalmic solution. 2. wash hands before each use. 3. before using the medication for the first time, be sure the safety seal on the bottle is unbroken. 4. tear off th

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution usp is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see warnings); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see warnings); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product. the drop-tainer® bottle is designed to assure the delivery of a precise dose of medication. before using your drop-tainer bottle, read the complete instructions carefully. 1. if you use other topically applied ophthalmic medications, they should be administered at least 10 minutes before or after timolol maleate ophthalmic solution. 2. wash hands before each use. 3. before using the medication for the first time, be sure the safety seal on th

United States - English - NLM (National Library of Medicine)

h.j. harkins company, inc. - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate ophthalmic solution is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see warnings); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see warnings); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product. sterile ophthalmic solution timolol maleate ophthalmic solution usp 0.25% and 0.5% instructions for use please follow these instructions carefully when using timolol maleate ophthalmic solution. use timolol maleate ophthalmic solution as prescribed by your doctor. 1. if you use other topically applied ophthalmic medications, they should be administered at least 10 minutes before or after the use of timolol maleate ophthalmic solution. 2. wash hands before eac

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate ophthalmic solution is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see warnings); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see warnings); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.

United States - English - NLM (National Library of Medicine)

medsource pharmaceuticals - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate ophthalmic solution is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see warnings); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see warnings); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol gfs 0.25% and 0.5% are indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol gfs is contraindicated in patients with: • bronchial asthma • history of bronchial asthma • severe chronic obstructive pulmonary disease • sinus bradycardia • second or third degree atrioventricular block • overt cardiac failure • cardiogenic shock • hypersensitivity to any component of this product. teratogenic effects pregnancy category c: teratogenicity studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of fetal malformations. although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. doses of 1,000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity. there are no adequate and well-controlled studies in pregnant women. timolol gfs should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. timolol maleate has been detected in human milk following oral and ophthalmic drug administration. because of the potential for serious adverse reactions in nursing infants from timolol gfs, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. safety and iop-lowering effect of timolol gfs 0.25% and 0.5% has been demonstrated in pediatric patients in a 3-month, multicenter, double-masked, active-controlled trial. no overall differences in safety or effectiveness have been observed between elderly and younger patients.

United States - English - NLM (National Library of Medicine)

akorn - dorzolamide hydrochloride (unii: qzo5366ew7) (dorzolamide - unii:9jdx055tw1), timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - dorzolamide 20 mg in 1 ml - dorzolamide hydrochloride-timolol maleate is indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target iop determined after multiple measurements over time). the iop-lowering of dorzolamide hydrochloride-timolol maleate administered twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol administered twice a day and 2% dorzolamide administered three times a day [see clinical studies (14)]. dorzolamide hydrochloride-timolol maleate is contraindicated in patients with bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease [see warnings and precautions (5.1)] . dorzolamide hydrochloride-timolol maleate is contraindicated in patients with sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, and cardiogenic shock [see warnings and precautions (5.2)] . do

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - latanoprost, quantity: 50 microgram/ml; timolol maleate, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; monobasic sodium phosphate monohydrate; water for injections; sodium hydroxide; dibasic sodium phosphate; hydrochloric acid; sodium chloride - reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins or other intraocular pressure lowering medications. latanoprost/timolol eye drops should not be used to initiate therapy.